Brokers Set Expectations for Chemours’ Q3 Earnings (NYSE:CC)

The Chemours Company (NYSE:CC) – Stock analysts at Zacks Research dropped their Q3 2026 earnings estimates for shares of Chemours in a note issued to investors on Tuesday, August 18th. Zacks Research analyst Team now anticipates that the specialty chemicals company will post earnings per share of $0.25 for the quarter, down from their previous forecast of $0.41. Zacks Research has a “Strong Sell” rating on the stock. The consensus estimate for Chemours’ current full-year earnings is $0.87 per share. Zacks Research also issued estimates for Chemours’ Q1 2027 earnings at $0.40 EPS, Q3 2027 earnings at $0.58 EPS and FY2028 earnings at $2.31 EPS.

A number of other research firms also recently issued reports on CC. The Goldman Sachs Group restated a “neutral” rating and set a $17.00 price target on shares of Chemours in a research note on Thursday, August 13th. Mizuho set a $22.00 price objective on Chemours in a research note on Wednesday, August 5th. BMO Capital Markets decreased their price objective on Chemours from $26.00 to $18.00 and set an “outperform” rating for the company in a report on Thursday, August 13th. JPMorgan Chase & Co. decreased their price target on shares of Chemours from $22.00 to $15.00 and set a “neutral” rating for the company in a research note on Thursday, August 13th. Finally, Royal Bank Of Canada dropped their price objective on shares of Chemours from $26.00 to $22.00 and set an “outperform” rating on the stock in a research note on Thursday, August 6th. Five analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $20.10.

Chemours Stock Down 1.1%

CC opened at $15.74 on Friday. Chemours has a one year low of $10.44 and a one year high of $28.67. The company has a debt-to-equity ratio of 18.98, a quick ratio of 0.88 and a current ratio of 1.66. The stock has a market capitalization of $2.37 billion, a P/E ratio of -8.24 and a beta of 1.43. The business’s 50-day simple moving average is $18.14 and its 200-day simple moving average is $20.04.

Chemours (NYSE:CC) last released its quarterly earnings data on Tuesday, August 4th. The specialty chemicals company reported $0.42 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.49 by ($0.07). The company had revenue of $1.59 billion during the quarter, compared to analyst estimates of $1.65 billion. Chemours had a negative net margin of 5.00% and a positive return on equity of 60.64%. The business’s revenue was down 1.5% on a year-over-year basis. During the same quarter in the prior year, the company earned ($2.54) EPS.

Chemours Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 15th. Shareholders of record on Friday, August 14th will be paid a $0.0875 dividend. This represents a $0.35 annualized dividend and a dividend yield of 2.2%. The ex-dividend date is Friday, August 14th. Chemours’s dividend payout ratio (DPR) is -18.32%.

Insider Buying and Selling at Chemours

In related news, insider Calderon Gerardo Familiar bought 1,935 shares of the company’s stock in a transaction dated Wednesday, August 12th. The shares were acquired at an average price of $15.53 per share, with a total value of $30,050.55. Following the completion of the acquisition, the insider owned 58,547 shares in the company, valued at approximately $909,234.91. This trade represents a 3.42% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Denise Dignam purchased 3,378 shares of the business’s stock in a transaction dated Tuesday, August 11th. The shares were bought at an average price of $14.95 per share, with a total value of $50,501.10. Following the purchase, the chief executive officer directly owned 339,916 shares of the company’s stock, valued at approximately $5,081,744.20. The trade was a 1.00% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last ninety days, insiders have purchased 8,663 shares of company stock worth $130,601. 0.85% of the stock is currently owned by insiders.

Institutional Trading of Chemours

Hedge funds have recently made changes to their positions in the company. BlackRock Inc. acquired a new position in shares of Chemours during the second quarter worth about $477,769,000. Vanguard Group Inc. lifted its position in Chemours by 2.8% in the fourth quarter. Vanguard Group Inc. now owns 17,920,868 shares of the specialty chemicals company’s stock valued at $211,287,000 after purchasing an additional 490,778 shares during the period. State Street Corp boosted its holdings in Chemours by 22.7% in the 2nd quarter. State Street Corp now owns 6,114,328 shares of the specialty chemicals company’s stock valued at $70,009,000 after purchasing an additional 1,131,682 shares in the last quarter. Ameriprise Financial Inc. boosted its holdings in Chemours by 13.8% in the 3rd quarter. Ameriprise Financial Inc. now owns 4,796,153 shares of the specialty chemicals company’s stock valued at $75,971,000 after purchasing an additional 580,089 shares in the last quarter. Finally, UBS Group AG increased its position in Chemours by 0.3% during the 3rd quarter. UBS Group AG now owns 4,754,492 shares of the specialty chemicals company’s stock worth $75,311,000 after purchasing an additional 14,865 shares during the period. Institutional investors and hedge funds own 76.26% of the company’s stock.

Chemours News Roundup

Here are the key news stories impacting Chemours this week:

• Positive Sentiment: Zacks raised its EPS forecasts for Q1 2027 to $0.40 from $0.39, Q3 2027 to $0.58 from $0.56, FY2027 to $2.05 from $1.95, Q4 2027 to $0.61 from $0.53, Q1 2028 to $0.56 from $0.55, and Q2 2028 to $0.65 from $0.61. These revisions suggest some confidence in Chemours’ longer-term earnings recovery. Analysts Offer Insights on Materials Companies: Chemours Company (CC) and Solstice Advanced Materials, Inc. (SOLS)
• Neutral Sentiment: The analyst changes are uneven rather than uniformly bullish: select estimates for 2027 and 2028 increased, while several near-term forecasts declined. Zacks’ current full-year EPS consensus is approximately $0.87-$0.88.
• Negative Sentiment: Zacks cut its Q3 2026 EPS estimate sharply to $0.25 from $0.41 and reduced its FY2026 forecast to $0.83 from $0.90. Q4 2026 EPS was also lowered to $0.11 from $0.12, indicating weaker expected results in the nearer term. The continued “Strong Sell” rating is likely weighing on investor sentiment.

Chemours Company Profile

Chemours Company, established in 2015 as a spin-off from E. I. du Pont de Nemours and Company, is a global chemistry organization headquartered in Wilmington, Delaware. Since its formation, Chemours has focused on delivering performance chemicals that help customers lower their carbon footprint, increase energy efficiency and conserve water. The company operates with a commitment to safety, environmental stewardship and innovation.

Chemours’ principal business activities are organized into three core segments.